Furthermore, it has been described the personalized Bridge-Vax vaccine which employs a hydrogel-based platform with autologous tumour cell membranes and that has shown improved efficacy in ovarian cancer by enhancing CD8+ T cells immunity and preventing tumour recurrence (148). The gene discussed is CD8A; the disease is neoplasm.